Invention Grant
- Patent Title: Use of AKT phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
-
Application No.: US14883685Application Date: 2015-10-15
-
Publication No.: US10288622B2Publication Date: 2019-05-14
- Inventor: Eran Ovadia , Irun R. Cohen , Johannes Herkel , Raanan Margalit , Meirav Pevsner-Fischer
- Applicant: Yeda Research and Development Co. Ltd. , Universitätsklinikum Hamburg-Eppendorf
- Applicant Address: IL Rehovot DE Hamburg
- Assignee: Yeda Research and Development Co. Ltd.,Universitätsklinikum Hamburg-Eppendorf
- Current Assignee: Yeda Research and Development Co. Ltd.,Universitätsklinikum Hamburg-Eppendorf
- Current Assignee Address: IL Rehovot DE Hamburg
- Main IPC: G01N33/53
- IPC: G01N33/53 ; C12Q1/64 ; G01N33/68 ; A61K38/08 ; A61K38/18 ; A61K38/30 ; A61K45/06 ; A61K31/343 ; C07K7/06 ; G01N33/543
Abstract:
The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogs and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
Public/Granted literature
- US20160033529A1 USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME Public/Granted day:2016-02-04
Information query
IPC分类:
